Founded in 1905, the National University of Singapore (NUS) offers a global approach to education, research, and entrepreneurship. NUS has 17 faculties and schools across three campuses. Close to 40,000 students from 100 countries enrich the community with their diverse social and cultural perspectives.
Research: Shaping the Future
NUS takes a holistic approach to research by integrating expertise across the natural and social sciences. Together, we answer the most challenging questions on how to live and work better.
On an island city-state vulnerable to rising sea levels, NUS researchers are driven to find Sustainability and Urban Solutions. Our research informs global policy on coastal defense, urban design, nature-based solutions, food-energy-water nexus, and the development of green energy technologies. In the Anthropocene, our behavioural and decision scientists work to understand and influence the impact of human consumption within cities.
NUS is also dedicated to Materials Research, where materials scientists, chemists, physicists, and engineers work together to unravel the secrets of the physical world and create materials for tomorrow’s technologies. Our researchers harness the principles which govern living matter to develop new functional intelligent materials for applications in everything from artificial neural networks to smart membranes.
We sometimes do the impossible. NUS researchers synthesised the world’s first one-atom-thick amorphous material. The discovery could finally settle a decades-old debate of exactly how atoms are arranged in amorphous solids and accelerate the development of data storage and energy devices.
Our researchers are also enabling people to live longer, higher-quality lives, with revolutions in Healthcare. During the COVID-19 pandemic, Duke-NUS researchers developed the first and only authorised SARS-CoV-2 neutralising antibody test product known as cPass™ SARS-CoV-2 Neutralisation Antibody Test, and the vaccine developed by Duke-NUS in partnership with Arcturus Therapeutics is undergoing human clinical trials globally.
NUS is at the forefront of cancer research, with breaking work in transforming the treatment of leukaemia. The cell-based therapy uses the body’s immune cells that have been altered in the lab to target and kill cancer cells. Our researchers have also developed the world’s first blood test that measures the effectiveness of cancer treatment within 24 hours after treatment initiation.
The interface between material and health sciences led to the creation of electronic skins that enable better prosthetic devices to mimic the human sense of touch, sense nearby objects without touching, and repair itself when damaged.
Underpinning our research is our respect and recognition for the rising role of technology. Within the NUS Smart Nation research cluster, computer scientists, engineers and social scientists collaborate to build resilience in the systems we rely on daily, by tackling issues of cybersecurity, logistics and operations, risk management, financial systems, and artificial intelligence-based technologies. NUS research on quantum key distribution has led to an increase in the long-term security of communication networks.
Our curiosity infuses the 150-hectare NUS campus, which serves as a living lab for the development and test-bedding of smart technologies, such as 5G network-empowered innovation in virtual reality, and district heating and cooling networks for energy-efficient cities. Our research places artificial intelligence and high technology at the service of society’s greatest needs and strives to make life ever more extraordinary.
1 May 2020 - 1 April 2021
Subject/journal group: All
The table to the right includes counts of all research outputs for National University of Singapore (NUS) published between 1 May 2020 - 1 April 2021 which are tracked by the Nature Index.
Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.
Note: Articles may be assigned to more than one subject area.
Outputs by subject (Share)
|Earth & Environmental Sciences||58||18.91|
Highlight of the month
Tracking cancer treatment from the get go
© TEK IMAGE/Science Photo Library/Getty Images
A simple blood test can reveal within 24 hours of starting a targeted cancer therapy whether it is having its desired effect or not.
Cancer therapies have come a long way. Conventional chemotherapies assail all rapidly growing cells in the body, giving rise to a wide range of side effects. In contrast, targeted cancer therapies attack specific molecules.
But monitoring whether these targeted therapies are working usually involves using imaging techniques several weeks after commencing a therapy or performing invasive biopsies.
Now, a nanotechnology platform developed by a team of National University of Singapore researchers can rapidly assess the progress of targeted cancer therapies from just a small blood sample taken from a patient.
The method involves analysing the contents of globules in the blood called extracellular vesicles. If they contain high levels of the drug, it indicates the therapy is being effective.
The researchers hope to make the technology commercially available within three years.
- Nature Nanotechnology 16, 734–742 (2021). doi: 10.1038/s41565-021-00872-w
Top articles by Altmetric score in current window
1 May 2020 - 1 April 2021
International vs. domestic collaboration by Share
- 21.3% Domestic
- 78.7% International
Note: Hover over the graph to view the percentage of collaboration.
Top 10 domestic collaborators by Share (61 total)
- National University of Singapore (NUS), Singapore
- Domestic institution
Agency for Science, Technology and Research (A*STAR), Singapore
Nanyang Technological University (NTU), Singapore
Duke-NUS Medical School, Singapore
Singapore Health Services Pte. Ltd. (SingHealth), Singapore
National University Health System (NUHS), Singapore
National University Cancer Institute (NCIS), Singapore
National University Heart Centre, Singapore (NUHCS), Singapore
Yale-NUS College, Singapore
Lee Kong Chian School of Medicine, Singapore
Singapore University of Technology and Design (SUTD), Singapore
Top 10 international collaborators by Share (2218 total)
- National University of Singapore (NUS), Singapore
- Foreign institution
Tianjin University (TJU), China
Joint School of National University of Singapore and Tianjin University, China
Chinese Academy of Sciences (CAS), China
Duke University, United States of America (USA)
Shenzhen University (SZU), China
SZU-NUS Collaborative Innovation Center for Optoelectronic Science and Technology, China
Massachusetts Institute of Technology (MIT), United States of America (USA)
French National Centre for Scientific Research (CNRS), France
Zhejiang University (ZJU), China
Harvard University, United States of America (USA)
Note: Collaboration is determined by the fractional count (Share), which is listed in parentheses.
Affiliated joint institutions and consortia
- CNRS Unité Mixte Internationale (UMI), Singapore
- A*Star SIMTech – NUS Joint Laboratory for Large-Area Flexible Hybrid Electronics, Singapore
- AI Singapore, Singapore
- ARC Centre of Excellence for Transformative Meta-Optical Systems, Australia
- Asian Genetic Epidemiology Network (AGEN), China
- Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium, South Korea
- Avian Phylogenomics Project, China
- Beijing-Hong Kong-Singapore Joint Center for Nonlinear and Complex Systems (BHS), China
- Berkeley Education Alliance for Research in Singapore (BEARS), Singapore
- BioMechanics of Cell-Cell Contact (BMC3), Singapore
- CQU-NUS Renewable Energy Materials and Devices Joint Laboratory, China
- Cambridge Centre for Advanced Research and Education in Singapore Ltd. (CARES), Singapore
- Clinical Imaging Research Centre (CIRC), Singapore
- Consortium for Refractive Error and Myopia (CREAM), Netherlands
- DIAGRAM Consortium, United Kingdom (UK)
- Duke-NUS Medical School, Singapore
- Early Growth Genetics Consortium (EGG), United States of America (USA)
- Energy and Environmental Sustainability Solutions for Megacities (E2S2), Singapore
- IPAL International Joint Lab, France
- International Consortium for Blood Pressure (ICBP), United States of America (USA)
- International Joint Laboratory for Advanced Fiber and Low-Dimension Materials, China
- International Joint Laboratory of Catalytic Chemistry, China
- International Joint Laboratory of Resource Chemistry, China
- International Lung Cancer Consortium (ILCCO), United States of America (USA)
- Jiangsu National Synergistic Innovation Center for Advanced Materials (SICAM), China
- Jiangsu-Singapore Joint Research Center on Organic/Bio Electronics and Information Displays, China
- Joint School of National University of Singapore and Tianjin University, China
- Lilly-NUS Centre for Clinical Pharmacology (LNUS), Singapore
- Merlion MajuLab, Singapore
- Molecular Mechanisms Underlying Inflammatory Diseases (MMID), Singapore
- NUS Synthetic Biology Research Consortium, Singapore
- NUS-HUJ-CREATE Programme for Inflammation Research, Singapore
- NUS-Imperial College Joint PhD Program, Singapore
- National University Health System (NUHS), Singapore
- SDU-NUS Center of Bio and Micro/Nano Functional Materials, China
- SZU-NUS Collaborative Innovation Center for Optoelectronic Science and Technology, China
- Sembcorp-NUS Corporate Laboratory, Singapore
- Singapore Centre on Environmental Life Sciences Engineering (SCELSE), Singapore
- Singapore Institute of Neurotechnology (SINAPSE), Singapore
- Singapore National Laboratory for Mass Spectrometry (SingMass), Singapore
- Singapore Peking Oxford Research Enterprise (SPORE), Singapore
- Singapore-Berkeley Research Initiative for Sustainable Energy (SinBeRISE), Singapore
- Singapore-Delft Water Alliance (SDWA), Singapore
- Singapore-ETH Centre (SEC), Singapore
- Singapore-MIT Alliance for Research and Technology (SMART), Singapore
- Singapore-Peking University Research Centre (SPURc), Singapore
- South Asian Type 2 Diabetes (SAT2D) Consortium, United Kingdom (UK)
- Temasek Life Sciences Laboratory (TLL), Singapore
- The AMD Gene Consortium, Germany
- The Blue Mountains Eye Study (BMES) - GWAS Group, Australia
- The HUGO Pan-Asian SNP Consortium, Thailand
- The SIGMA Type 2 Diabetes Consortium (SIGMA T2D Consortium), United States of America (USA)
- Translational Laboratory in Genetic Medicine (TLGM), Singapore
- Type 2 Diabetes Genetic Exploration by Next-generation sequencing in multi-Ethnic Samples (T2D-GENES) Consortium, United States of America (USA)
- WIL@NUS Corporate Laboratory, Singapore
- Waseda Bioscience Research Institute in Singapore (WABIOS), Singapore
- Yale-NUS College, Singapore
Numerical information only is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.